

# Russell W Madison

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6146432/publications.pdf>

Version: 2024-02-01

87  
papers

2,156  
citations

393982

19  
h-index

243296

44  
g-index

87  
all docs

87  
docs citations

87  
times ranked

2757  
citing authors

#	ARTICLE	IF	CITATIONS
1	Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2022, 81, 37-47.	0.9	16
2	The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA. <i>Clinical Cancer Research</i> , 2022, 28, 728-737.	3.2	20
3	Comprehensive genomic profiling (CGP)-informed personalized molecular residual disease (MRD) detection: An exploratory analysis from the PREDATOR study of metastatic colorectal cancer (mCRC) patients undergoing surgical resection.. <i>Journal of Clinical Oncology</i> , 2022, 40, 187-187.	0.8	5
4	Molecular residual disease (MRD) detection with a tissue comprehensive genomic profiling (CGP)-informed personalized monitoring assay: An exploratory analysis of the IMvigor-010 observation arm.. <i>Journal of Clinical Oncology</i> , 2022, 40, 448-448.	0.8	2
5	The Genomics of Colorectal Cancer in Populations with African and European Ancestry. <i>Cancer Discovery</i> , 2022, 12, 1282-1293.	7.7	28
6	Clustered 8-Oxo-Guanine Mutations and Oncogenic Gene Fusions in Microsatellite-Unstable Colorectal Cancer. <i>JCO Precision Oncology</i> , 2022, 6, e2100477.	1.5	2
7	CtDNA shed as a tool to select immune checkpoint inhibitors (ICPI) with or without chemotherapy for patients (pts) with advanced non-small cell lung cancer (aNSCLC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 9045-9045.	0.8	3
8	Molecular Characterization of Mesothelioma: Impact of Histologic Type and Site of Origin on Molecular Landscape. <i>JCO Precision Oncology</i> , 2022, , .	1.5	10
9	Landscape of homologous recombination reversion mutations in pancreaticobiliary malignancies.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4156-4156.	0.8	1
10	Predicting the Pathologic Complete Response After Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 48-53.	3.0	30
11	Urothelial Cancers with Small Cell Variant Histology Have Confirmed High Tumor Mutational Burden, Frequent TP53 and RB Mutations, and a Unique Gene Expression Profile. <i>European Urology Oncology</i> , 2021, 4, 297-300.	2.6	18
12	Clinicopathologic, genomic and protein expression characterization of 356 ROS1 fusion driven solid tumors cases. <i>International Journal of Cancer</i> , 2021, 148, 1778-1788.	2.3	14
13	In search of novel synthetic lethality anti-cancer drug targets in intrahepatic cholangiocarcinoma: MTAP genomic loss.. <i>Journal of Clinical Oncology</i> , 2021, 39, 337-337.	0.8	0
14	Comprehensive genomic profiling (CGP) to reveal new opportunities and challenges in muscle-invasive bladder cancer (MIBC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 479-479.	0.8	0
15	RAS Amplification as a Negative Predictor of Benefit from Anti-EGFR-Containing Therapy Regimens in Metastatic Colorectal Cancer. <i>Oncologist</i> , 2021, 26, 469-475.	1.9	7
16	Novel synthetic lethality (SL) anti-cancer drug target in urothelial bladder cancer (UCB) based on MTAP genomic loss: Incidence and correlations in standard of care (SOC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 485-485.	0.8	1
17	Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms. <i>Clinical Cancer Research</i> , 2021, 27, 3094-3105.	3.2	101
18	Real-world overall survival (OS) and time to therapy discontinuation (TTD) of patients (pts) with mCRPC treated with second-generation novel hormonal therapies (NHT) associated with tissue-based comprehensive genomic profiling (CGP).. <i>Journal of Clinical Oncology</i> , 2021, 39, 142-142.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer to identify targetable BRCA alterations and AR resistance mechanisms.. Journal of Clinical Oncology, 2021, 39, 25-25.	0.8	2
20	Plasma circulating tumor DNA (ctDNA) fraction and real-world overall survival (rwOS) in metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2021, 39, e17035-e17035.	0.8	0
21	ERBB2 copy number (CN) as a quantitative biomarker for real-world (RW) outcomes to anti-HER2 therapy in advanced gastroesophageal adenocarcinoma (adv GEA).. Journal of Clinical Oncology, 2021, 39, 4045-4045.	0.8	2
22	Genomic landscape of <i>MSH6</i> -mutated clinically advanced castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2021, 39, 5062-5062.	0.8	1
23	Incidence and heterogeneity of C797S and other EGFR resistance mutations on routine comprehensive genomic profiling (CGP).. Journal of Clinical Oncology, 2021, 39, 9101-9101.	0.8	2
24	Comprehensive molecular profiling of pleural mesothelioma according to histologic subtype.. Journal of Clinical Oncology, 2021, 39, 8555-8555.	0.8	0
25	Analysis of real-world (RW) data for metastatic breast cancer (mBC) patients (pts) with somatic <i>BRCA1/2</i> ( <i>sBRCA</i> ) or other homologous recombination (HR)-pathway gene mutations (muts) treated with PARP inhibitors (PARPi).. Journal of Clinical Oncology, 2021, 39, 10512-10512.	0.8	1
26	Using real-world outcomes to evaluate the predictive power of tissue-assessed genomic biomarkers for taxane versus novel hormonal therapy (NHT) outcomes in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2021, 39, 5054-5054.	0.8	0
27	Abstract 2231: Utility of plasma tumor fraction (TF) to inform sensitivity of FoundationOne Liquid CDx (F1LCDx). Cancer Research, 2021, 81, 2231-2231.	0.4	6
28	Contrasting genomic profiles from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancer. Cancer, 2021, 127, 4557-4564.	2.0	5
29	Real-world association of HER2/ <i>ERBB2</i> concordance with trastuzumab clinical benefit in advanced esophagogastric cancer. Future Oncology, 2021, 17, 4101-4114.	1.1	7
30	Characterization of Non-Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns. JCO Precision Oncology, 2021, 5, 1354-1376.	1.5	12
31	Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature, 2021, 597, 732-737.	13.7	185
32	Genomic profiling of solid tumors harboring BRD4-NUT and response to immune checkpoint inhibitors. Translational Oncology, 2021, 14, 101184.	1.7	13
33	Comprehensive genomic profiling of histologic subtypes of urethral carcinomas. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 731.e1-731.e15.	0.8	7
34	Cabozantinib Plus Durvalumab in Patients With Advanced Urothelial Carcinoma After Platinum Chemotherapy: Safety and Preliminary Activity of the Open-Label, Single-Arm, Phase 2 ARCADIA Trial. Clinical Genitourinary Cancer, 2021, 19, 457-465.	0.9	8
35	Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma. European Urology Focus, 2021, 7, 1339-1346.	1.6	58
36	The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA. Oncologist, 2020, 25, e39-e47.	1.9	13

#	ARTICLE	IF	CITATIONS
37	Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies. <i>European Urology</i> , 2020, 77, 439-446.	0.9	228
38	Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. <i>European Urology</i> , 2020, 77, 636-643.	0.9	75
39	Characterization of Clinical Cases of Malignant PEComa via Comprehensive Genomic Profiling of DNA and RNA. <i>Oncology</i> , 2020, 98, 905-912.	0.9	27
40	Targetable gene fusions and aberrations in genitourinary oncology. <i>Nature Reviews Urology</i> , 2020, 17, 613-625.	1.9	35
41	Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling. <i>Lung Cancer</i> , 2020, 148, 69-78.	0.9	25
42	&lt;p&gt;Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the &lt;em&gt;ALK&lt;/em&gt; Gene Have Durable Responses to ALK Kinase Inhibitors&lt;p&gt;. <i>Lung Cancer: Targets and Therapy</i> , 2020, Volume 11, 33-39.	1.3	2
43	U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 4785-4794.	3.2	63
44	Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e543-e556.	0.9	22
45	Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder. <i>European Urology</i> , 2020, 77, 548-556.	0.9	41
46	Urothelial cancer harbours <i>EGFR</i> and <i>HER2</i> amplifications and exon 20 insertions. <i>BJU International</i> , 2020, 125, 739-746.	1.3	14
47	Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer. <i>Scientific Reports</i> , 2020, 10, 22087.	1.6	21
48	Primary tumor (p-bx) versus metastatic tumor (m-bx) tissue versus liquid biopsy (lb) in intrahepatic cholangiocarcinoma (IHCC): A comparative comprehensive genomic profiling (CGP) study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4579-4579.	0.8	1
49	Final results of PEANUT: Pembrolizumab and nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as salvage therapy for metastatic urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 5017-5017.	0.8	2
50	Association of BRCA alteration (alt) type with real-world (RW) outcomes to PARP inhibitors (PARPi) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 5527-5527.	0.8	3
51	Characterization of 1,387 NSCLCs with MET exon 14 (METex14) skipping alterations (SA) and potential acquired resistance (AR) mechanisms.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9511-9511.	0.8	22
52	Primary versus metastatic intrahepatic cholangiocarcinoma: A comparative comprehensive genomic profiling (CGP) study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 578-578.	0.8	4
53	Interim results of PEANUT: pembrolizumab and nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as salvage therapy for metastatic urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 494-494.	0.8	0
54	Association of real-world agreement between HER2 expression and ERBB2 amplification with trastuzumab therapy benefit in advanced gastric/esophageal (adv GE) cancer patients (pts).. <i>Journal of Clinical Oncology</i> , 2020, 38, 310-310.	0.8	0

#	ARTICLE	IF	CITATIONS
55	Pan-tumor analyses of kinase fusions detected in circulating tumor DNA (ctDNA) and concordance with paired tissue.. Journal of Clinical Oncology, 2020, 38, 3517-3517.	0.8	0
56	Real-world (RW) outcomes for advanced non-small cell lung cancer (aNSCLC) patients (pts) with <i>EGFR</i> exon 19 deletions (x19del) stratified by deletion size.. Journal of Clinical Oncology, 2020, 38, 9591-9591.	0.8	0
57	Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma. Oncotarget, 2019, 10, 4018-4025.	0.8	118
58	<i>FGFR2</i>-Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape. Oncologist, 2019, 24, 1462-1468.	1.9	16
59	&lt;p&gt;TKI-resistant &lt;em&gt;ALK&lt;/em&gt;-rearranged lung adenocarcinoma with secondary CTNNB1 p.S45V and tertiary ALK p.I1171N mutations&lt;/p&gt;. Lung Cancer: Targets and Therapy, 2019, Volume 10, 81-86.	1.3	1
60	Atypical <i>RAS</i> Mutations in Metastatic Colorectal Cancer. JCO Precision Oncology, 2019, 3, 1-11.	1.5	1
61	Comprehensive genomic profiling (CGP) of upper-tract (UTUC) and bladder (BUC) urothelial carcinoma reveals opportunities for therapeutic and biomarker development.. Journal of Clinical Oncology, 2019, 37, 4581-4581.	0.8	6
62	Characterization of 648 non-small cell lung cancer (NSCLC) cases with 28 unique <i>HER2</i> exon 20 insertions.. Journal of Clinical Oncology, 2019, 37, 9063-9063.	0.8	7
63	Anal melanoma: A comparative comprehensive genomic profiling study.. Journal of Clinical Oncology, 2019, 37, 551-551.	0.8	1
64	<i>FGFR2</i>-altered gastroesophageal adenocarcinomas (GEA) are a rare clinicopathologic entity with a distinct genomic landscape.. Journal of Clinical Oncology, 2019, 37, 72-72.	0.8	1
65	<i>KRAS</i> amplification and mutation are independent events in gastroesophageal adenocarcinomas (GEA).. Journal of Clinical Oncology, 2019, 37, 70-70.	0.8	1
66	Analysis of EGFR mutant upper tract and bladder urothelial carcinoma (UC) reveals distinct mutational landscape.. Journal of Clinical Oncology, 2019, 37, 416-416.	0.8	0
67	First survival outcomes and additional secondary analyses from PURE-01: Pembrolizumab (pembro) before radical cystectomy (RC) in muscle-invasive urothelial bladder carcinoma (MIBC).. Journal of Clinical Oncology, 2019, 37, 391-391.	0.8	1
68	Analysis of HER2 mutant bladder urothelial carcinomas reveals unique mutational signature.. Journal of Clinical Oncology, 2019, 37, 460-460.	0.8	0
69	Squamous-cell carcinoma variant histology (SCC-VH) in muscle-invasive bladder cancer (MIBC): A comprehensive clinical, genomic, and therapeutic assessment from multiple datasets.. Journal of Clinical Oncology, 2019, 37, 4535-4535.	0.8	0
70	Towards the noninvasive identification of pathologic responders to neoadjuvant pembrolizumab in muscle-invasive urothelial bladder cancer (MIBC).. Journal of Clinical Oncology, 2019, 37, 4540-4540.	0.8	0
71	Analysis of <i>EGFR</i> mutant urothelial carcinoma (UC) reveals distinct mutational landscape.. Journal of Clinical Oncology, 2019, 37, 4545-4545.	0.8	0
72	KRAS amplification and mutation as independent events in gastroesophageal adenocarcinomas (GEA).. Journal of Clinical Oncology, 2019, 37, e15565-e15565.	0.8	0

#	ARTICLE	IF	CITATIONS
73	FGFR2: A pan-genomic target.. Journal of Clinical Oncology, 2019, 37, 3099-3099.	0.8	2
74	Anal melanoma: A comparative comprehensive genomic profiling study.. Journal of Clinical Oncology, 2019, 37, 9566-9566.	0.8	0
75	Loss of Heterozygosity of FLT3-ITD Is Common in Acute Myeloid Leukemia and May be a More Consistent Prognostic Marker Than FLT3-ITD Allele Frequency. Blood, 2019, 134, 1437-1437.	0.6	2
76	Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma. British Journal of Cancer, 2018, 118, 1238-1242.	2.9	33
77	Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. Journal of Clinical Oncology, 2018, 36, 3353-3360.	0.8	474
78	Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC. Journal of Thoracic Oncology, 2018, 13, 1560-1568.	0.5	158
79	Clinical Activity of Crizotinib in Lung Adenocarcinoma Harboring a Rare ZCCHC8-ROS1 Fusion. Journal of Thoracic Oncology, 2018, 13, e148-e150.	0.5	7
80	Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors. Journal of Thoracic Oncology, 2018, 13, 1312-1323.	0.5	103
81	Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma. European Urology, 2018, 74, 124-128.	0.9	52
82	Comparison of tumor mutational burden (TMB) in PBRM1/BAP1-based subsets of advanced renal cell carcinoma (aRCC).. Journal of Clinical Oncology, 2018, 36, 634-634.	0.8	1
83	Co-existing alterations in cell-cycle pathway genes and impact on benefit from trastuzumab in advanced esophagogastric cancers (EGC): Analysis of 527 Her2-amplified cases.. Journal of Clinical Oncology, 2018, 36, 4063-4063.	0.8	0
84	Landscape of kinase rearrangements (kRE) detected in circulating tumor DNA (ctDNA).. Journal of Clinical Oncology, 2018, 36, 12041-12041.	0.8	0
85	Objective response to mTOR inhibition in a metastatic collision tumor of the liver composed of melanoma and adenocarcinoma with TSC1 loss: a case report. BMC Cancer, 2017, 17, 197.	1.1	5
86	Genomic profiling of nephrectomy and metastatic sites in patients with advanced clear cell renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2017, 35, 513-513.	0.8	1
87	Comprehensive genomic profiling to identify clinically relevant genomic alterations in patients with advanced penile cancers.. Journal of Clinical Oncology, 2016, 34, 4573-4573.	0.8	0